Figure 4.

PAH-specific drug therapies (patient record data). Response to the study question “Please select from the options listed which PAH-specific drugs this patient is currently receiving?” A, Drug category; B, Monotherapy, dual combination, and triple or greater therapy. Probability test pairwise comparisons (with Bonferroni correction) were significantly (P < 0.05) different versus the corresponding category in ^†the US, ^‡Europe, ^§Argentina, or ^¶Japan. AR: Argentina; ERAs: endothelin receptor antagonists; EU: Europe; JP: Japan; PAH: pulmonary arterial hypertension; PDE-5: phosphodiesterase 5; US: United States.